Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Arbutus Biopharma CorporationNASDAQ: ABUS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $4.12M fell 54.0% year over year, ahead of the -57.1% change in trailing-twelve-month research & development. Sequentially, it fell 17.7% from the prior quarter. Over 3 fiscal years it compounded at -33.1% a year.
Context
- Research & development amounted to 179.2% of revenue in FY2025, down 696.4 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -54.0% holds above the trailing-twelve-month pace of -57.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 25.24M USD
- Year-over-year change
- -53.3%
- 4-year CAGR
- -21.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.24M | -53.3% |
| FY2024 | 2024-12-31 | 54.04M | -26.7% |
| FY2023 | 2023-12-31 | 73.7M | -12.7% |
| FY2022 | 2022-12-31 | 84.41M | +28.9% |
| FY2021 | 2021-12-31 | 65.5M | — |
Research & Development vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 research & development of $20.4M is the 8th highest of the 9 companies compared; the peer median is $125.45M.
- Its year-over-year change of -57.1% is the lowest of 8, against a peer median of +10.1%.
- Research & development amounts to 10.7% of revenue for ABUS, versus a peer median of 147.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.51B | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $739.14M | +21.7% | +29.3% | 164.0% | |
| LTM Mar 2026 | $446.24M | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $61.84M | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $20.4M | -57.1% | -33.1% | 10.7% | |
| LTM Mar 2026 | $19.2M | +1.2% | +17.6% | — | |
| Peer median (excluding ABUS) | $125.45M | +10.1% | +16.0% | 147.9% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 363K |
| Gross Profit | 10.99M | 39.02M | 18.14M | 6.17M | 13.72M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Research & Development | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| Selling, General & Admin | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Operating Expenses | 84.51M | 104.48M | 96.24M | 82.49M | 40.77M |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| EBITDA | (71.64M) | (61.86M) | (70.99M) | (68.4M) | (33.04M) |
| EBITDA Margin | -652.0% | -158.5% | -391.3% | -1108.5% | -234.6% |
| Operating Income | (73.52M) | (65.46M) | (78.1M) | (76.32M) | (27.05M) |
| Operating Margin | -669.1% | -167.8% | -430.5% | -1236.7% | -192.1% |
| Interest Income | 127K | 2.19M | 5.69M | 6.59M | 4.07M |
| Interest Expense | 2.86M | 1.73M | 459K | 137K | 97K |
| Other Income / Expenses | (2.73M) | 444K | 5.25M | 6.4M | (6.45M) |
| Income Before Tax | (76.25M) | (65.01M) | (72.85M) | (69.92M) | (33.5M) |
| Pre-Tax Margin | -693.9% | -166.6% | -401.6% | -1133.0% | -237.9% |
| Income Tax Expense | 0 | 4.44M | 0 | 0 | 0 |
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Net Margin | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (Basic) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| EPS (Diluted) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| Weighted Avg Shares | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Weighted Avg Shares (Diluted) | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.